Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Akero Therapeutics Inc (AKRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: AKRO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $76.3
1 Year Target Price $76.3
| 9 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.91% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.48B USD | Price to earnings Ratio - | 1Y Target Price 76.3 |
Price to earnings Ratio - | 1Y Target Price 76.3 | ||
Volume (30-day avg) 12 | Beta -0.16 | 52 Weeks Range 21.02 - 58.40 | Updated Date 06/30/2025 |
52 Weeks Range 21.02 - 58.40 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.75 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -18.52% | Return on Equity (TTM) -27.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3835587076 | Price to Sales(TTM) - |
Enterprise Value 3835587076 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.77 | Shares Outstanding 79717600 | Shares Floating 66004554 |
Shares Outstanding 79717600 | Shares Floating 66004554 | ||
Percent Insiders 1.39 | Percent Institutions 109.29 |
Analyst Ratings
Rating 4 | Target Price 76.3 | Buy 3 | Strong Buy 9 |
Buy 3 | Strong Buy 9 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Akero Therapeutics Inc
Company Overview
History and Background
Akero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH). It was founded in 2017. The company's lead product candidate is efruxifermin (EFX).
Core Business Areas
- NASH Drug Development: Akero's primary focus is on the research, development, and commercialization of therapies for NASH and other metabolic diseases. This includes clinical trials, regulatory submissions, and potential future manufacturing and marketing activities.
Leadership and Structure
Andrew Cheng, M.D., Ph.D., is the President and CEO. The company has a board of directors and a management team overseeing research, development, clinical trials, finance, and other key functions.
Top Products and Market Share
Key Offerings
- Efruxifermin (EFX): EFX is Akero's lead product candidate, a fibroblast growth factor 21 (FGF21) analogue being developed for the treatment of NASH. It is currently in Phase 2b/3 clinical trials. There is no current revenue from this product since it is not yet approved. Competitors include Viking Therapeutics (VKTX), Madrigal Pharmaceuticals (MDGL), 89bio (ETNB).
Market Dynamics
Industry Overview
The NASH market is a large and rapidly growing market due to the increasing prevalence of obesity and diabetes, which are risk factors for NASH. There are currently limited approved treatments for NASH, creating a significant unmet medical need.
Positioning
Akero aims to be a leader in the NASH treatment space with EFX, which has shown promising results in clinical trials. The company's FGF21 analogue approach differentiates it from some competitors.
Total Addressable Market (TAM)
The NASH market is estimated to be tens of billions of dollars. Akero, if successful, is positioned to capture a significant portion of the TAM with EFX.
Upturn SWOT Analysis
Strengths
- Promising clinical trial data for EFX
- Experienced management team
- Strong intellectual property position
- Focused approach on NASH
Weaknesses
- Dependence on successful development and approval of EFX
- High cash burn rate
- No currently approved products
- Potential for clinical trial setbacks
Opportunities
- Potential for accelerated regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion into other metabolic disease indications
- Acquisition by a larger pharmaceutical company
Threats
- Competition from other companies developing NASH treatments
- Regulatory hurdles
- Clinical trial failures
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- MDGL
- VKTX
- ETNB
Competitive Landscape
Akero has a competitive FGF21 analogue approach with promising data. Competition is stiff from larger pharma and other biotech companies with different mechanisms of action.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth is defined by expansion of the clinical trials. As of now there are no marketable products
Future Projections: Future growth is dependent on the successful commercialization of EFX and expansion into other metabolic disease indications. Analyst projections vary, but generally anticipate significant revenue growth upon potential approval of EFX.
Recent Initiatives: Recent initiatives include progressing EFX through Phase 2b/3 clinical trials and preparing for potential regulatory submissions.
Summary
Akero Therapeutics is a clinical-stage biopharmaceutical company focused on NASH. Its lead drug, efruxifermin, shows promise but faces competition and regulatory hurdles. The company has a strong financial position to continue clinical trials, but its future is tied to the success of EFX. It requires successful navigation of clinical trials and regulatory processes to realize its potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings, Company Website, Analyst Reports (Yahoo Finance, Google Finance, etc.)
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market share estimates are approximate and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Akero Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2019-06-20 | President, CEO & Director Dr. Andrew Cheng M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 69 | Website https://akerotx.com |
Full time employees 69 | Website https://akerotx.com | ||
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.